TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CanSino Biologics, Inc. Class H ( (HK:6185) ) has provided an announcement.
CanSino Biologics Inc. announced the successful passage of all resolutions at its 2025 second extraordinary general meeting, including amendments to the Articles of Association and the election of new independent non-executive directors. These changes, effective from November 27, 2025, are expected to enhance the company’s governance structure and strategic direction, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (HK:6185) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in the People’s Republic of China, primarily engaged in the development and production of innovative vaccines. The company focuses on providing solutions for global public health challenges, with a market emphasis on vaccine innovation and distribution.
Average Trading Volume: 1,161,225
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.37B
Learn more about 6185 stock on TipRanks’ Stock Analysis page.